Asia
Lummy Pharmaceutical Gets Marketing Nod for API
Chongqing Lummy Pharmaceutical (SHE:300006) received marketing approval from China's National Medical Products Administration for triptorelin acetate, an active pharmaceutical ingredient, according to a Shanghai bourse filing on Saturday.The API was developed as an infertility treatment by Lummy Pharmaceutical, a subsidiary of Guangxi Wuzhou Zhongheng (SHA:600252).
SHA:600252SHE:300006